Management of Poorly Controlled Type 2 Diabetes

Introduction to Treatment Approach

The American Diabetes Association recommends intensification of treatment for patients with poorly controlled type 2 diabetes, with a priority on adding an SGLT2 inhibitor to reduce cardiovascular and renal risk while improving glycemic control, especially in patients with high A1C levels like 9.0% 1, 2
The current treatment regimen for a patient with an A1C of 9.0% indicates poor glycemic control despite being on multiple medications, including basal insulin and maximum dose GLP-1 RA, suggesting the need for treatment intensification 1, 2

Adding an SGLT2 inhibitor with proven cardiovascular and renal benefits to the current regimen is recommended, regardless of A1C goal, due to the patient's age and higher cardiovascular risk, as suggested by the American College of Cardiology 4, 1
SGLT2 inhibitors provide complementary benefits to GLP-1 RAs and insulin by different mechanisms of action, which can lead to improved glycemic control and reduced cardiovascular risk, according to the American Heart Association 1, 2
The American Diabetes Association recommends evaluating the current insulin regimen for optimization, considering conversion of sliding scale to fixed mealtime insulin doses if significant glycemic variability is present, to improve glycemic control 3, 2

Reassessing A1C in 3 months after treatment changes is crucial, as recommended by the American Diabetes Association, to evaluate the effectiveness of the new treatment approach and make necessary adjustments 3, 1
Monitoring for hypoglycemia, especially with the combination of insulin and other glucose-lowering medications, is essential to prevent and manage hypoglycemic events, as emphasized by the Endocrine Society 4, 2
Evaluating kidney function regularly, particularly when using SGLT2 inhibitors, is important to assess the risk of kidney disease and adjust treatment accordingly, as recommended by the National Kidney Foundation 1, 5

Patients with poorly controlled diabetes, like the 68-year-old patient with an A1C of 9.0%, are at high risk for both microvascular and macrovascular complications, highlighting the need for comprehensive and aggressive management, as stated by the American College of Cardiology 4, 9
The combination of GLP-1 RA and SGLT2 inhibitor has complementary mechanisms and can provide additive benefits for both glycemic control and cardiorenal protection, according to the European Association for the Study of Diabetes 1, 5
Weight management should be considered as part of the overall treatment strategy, with both GLP-1 RAs and SGLT2 inhibitors offering weight reduction benefits, as recommended by the Obesity Society 5, 2